SMMT NASDAQ
Credit Risk of going bust: lower than 78% of companies Debt: 0.2% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.00 (down more than 99.9%), Summit Therapeutics Inc. would be worth roughly what it owes.
Total debt $20.4M against a stock market value of $11.57B.
Distance to default 9.27 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $12.0M (short-term plus half of long-term), stock volatility 71.9%; Altman Z'' -8.55. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Miami, FL 33131
US
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Anand Bhaskar | A-Award | 100,000 | — | 2026-10-08 |
| DUGGAN ROBERT W | P-Purchase | 3,810,000 | $13.12 | 2026-06-12 |
| Zanganeh Mahkam | P-Purchase | 3,810,000 | $13.12 | 2026-06-12 |
| Soni Manmeet Singh | P-Purchase | 25,000 | $14.46 | 2026-06-04 |
| Soni Manmeet Singh | P-Purchase | 25,000 | $14.43 | 2026-06-04 |